AG 1024-CAS 65678-07-1-Calbiochem

C₁₄H₁₃BrN₂O

305.17

A cell-permeable, reversible, substrate competitive, and specific inhibitor of insulin-like growth factor-1 (IGF-1) and insulin receptor kinases with significantly lower IC₅₀ values for IGF-1 than for insulin receptors. Induces apoptosis by downregulating the expression of phospho-Akt1 and Bcl-2; and increasing the expression of Bax, p53 and p21. Reported to enhance the radiosensitivity of human breast cancer cells.
A cell-permeable, reversible, substrate competitive, and specific inhibitor of insulin-like growth factor-1 (IGF-1) and insulin receptor tyrosine kinase activity. Exhibits lower IC₅₀ values for IGF-1 than for the insulin receptor. Also inhibits insulin-stimulated cellular proliferation.

Cell permeable: yes
Primary Target
IGF-1
Product does not compete with ATP.
Reversible: yes

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 2 months at -20°C.

Wen, B., et al. 2001. Br. J. Cancer85, 2017.
Parrizas, M., et al. 1997. Endocrinology138, 1427.
Ohmichi, M., et al. 1993. Biochemistry32, 4650.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥98% (HPLC)

solid

Calbiochem^®

OK to freeze
protect from light

off-white to yellow

DMSO: 10 mg/mL

ambient

−20℃

1S/C14H13BrN2O/c1-14(2,3)11-5-9(4-10(7-16)8-17)6-12(15)13(11)18/h4-6,18H,1-3H3

ABBADGFSRBWENF-UHFFFAOYSA-N

1 mg in Plastic ampoule
Packaged under inert gas

11 - Combustible Solids

WGK 3